Translational Genomics Research Institute

The Translational Genomics Research Institute (TGen), is a non-profit genomics research institute based in Arizona, United States. TGen seeks to employ genetic discoveries to improve disease outcomes by developing smarter diagnostics and targeted therapeutics.

Translational Genomics Research Institute
Research Institute
IndustryGenomics
FoundedJuly 2002, Phoenix, Arizona, United States
HeadquartersPhoenix, Arizona, United States
Key people
Jeffrey Trent
Revenue
  • $51.7 million (2007)[1]
  • $18.3 million (2003)[1]
Number of employees
258 (2008)[1]
Websitehttp://www.tgen.org
The Translational Genomics Research Institute at night.

History and activities

TGen was established in 2002 by Jeffrey Trent in Phoenix, Arizona, United States. The Institute began with a US$100 million investment from Arizona public- and private-sector investors.[1]

TGen conducts research on a number of human disorders including Alzheimer's disease, Autism, Parkinson's, Diabetes and numerous forms of cancer and a variety of other complex human diseases. This internationally recognized institute has helped to generate a strong foundation for Arizona's growing role in scientific research and cutting edge biotechnology.

The emerging field of translational genomics research harnesses the power of new discoveries resulting from the Human Genome Project and applying them to the development of improved diagnostics, prognostics and therapies for cancer, neurological disorders, diabetes and other complex diseases.

TGen Administration
  • Jeffrey M. Trent, Ph.D., President & Scientific Director[1]
  • Sunil Sharma, MD FACP, Deputy Director
  • Michael Bassoff, President, TGen Foundation
  • Daniel Von Hoff, M.D., F.A.C.P., Executive Vice President, Physician-in-Chief[2]
  • Tess Burleson, MBA, CPA, Chief Operating Officer and President, TGen Accelerators
  • Chuck Coleson, Chief Financial Officer
  • Galen Perry, Vice President, Marketing and Communications
  • Janine Tilli, Vice President, Human Resources
  • Kendall Van Keuren-Jensen, co-Director[3]
gollark: I'm prepared, coincidentally, with three spare slots.
gollark: It's useless because nobody knows what you want.
gollark: Also, the wants thing is a bit different, because if you don't fill it in your trade is useless anyway.
gollark: I don't know who they are anyway...
gollark: New users, or ones who are multi scrollers, yes.

References
  1. Alltucker, Ken (16 April 2008). "5-year-old TGen fights for funding". The Arizona Republic. Archived from the original on 17 January 2013.
  2. Alltucker, Ken (16 April 2008). "Cancer-drug trials show promise". The Arizona Republic. Archived from the original on 17 January 2013.
  3. "Exosome Sciences, TGen to Launch Study of CTE in Former NFL Players". CellOMICs. 26 March 2018. Retrieved 27 March 2018.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.